Core Insights - Insilico Medicine, a clinical-stage biopharmaceutical company driven by generative artificial intelligence, has announced a strategic drug development collaboration with Qilu Pharmaceutical Group and its subsidiary, Shanghai Qilu Pharmaceutical Research Center [1] - The partnership will leverage Insilico's proprietary Pharma.AI platform to develop small molecule inhibitors targeting specific pathways, focusing on the management of cardiovascular and metabolic diseases [1] - The total contract value exceeds HKD 931 million, which includes milestone payments for development and sales, as well as a share of future net sales [1] Company Summary - Insilico Medicine specializes in AI-driven drug discovery and development, particularly in the field of small molecule drugs for metabolic diseases [1] - Qilu Pharmaceutical Group will handle the subsequent development and commercialization of the drugs developed through this collaboration [1] Financial Summary - The collaboration agreement is valued at over HKD 931 million, indicating significant financial commitment and potential for revenue generation through milestone payments and sales sharing [1]
英矽智能：齐鲁制药达成总额9.31亿港元药物研发合作